CINXE.COM
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
<!DOCTYPE html> <html lang="en"> <head id="Head1"><meta charset="utf-8" /><title> Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan </title><link href="../../../../Content/Site.css" rel="stylesheet" /><link href="../../../../Content/bootstrap-3.3.2-dist/css/bootstrap.min.css" rel="stylesheet" /><link href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css" rel="stylesheet" /><link href="../../../../Content/Custom.css" rel="stylesheet" /><link href="../../../../Content/CustomSubPage.css" rel="stylesheet" /><link href="../../../favicon.ico" rel="shortcut icon" type="image/x-icon" /> <script src="/Scripts/modernizr-2.5.3.js"></script> <meta name="viewport" content="width=device-width" /> <script type="text/javascript" src="https://www.jcnnewswire.com/jquery/jquery-latest.min.js"> </script> <script type="text/javascript" src="https://www.jcnnewswire.com/jquery/jquery.fancybox.pack.js?v=2.1.5"></script> <link rel="stylesheet" type="text/css" href="https://www.jcnnewswire.com/jquery/jquery.fancybox.css?v=2.1.5" media="screen"> <style> .lang li { display:inline; } .lang a { color:#fff; } </style> </head> <body> <form method="post" action="./Eisai-Signs-Research-Collaboration-Agreement-with-The-National-Center-of-Neurology-and-Psychiatry-to" onsubmit="javascript:return WebForm_OnSubmit();" id="Form1"> <div class="aspNetHidden"> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="/wEPDwUJMjIwMDIyMjcyZGS0ekUELnr7FYRFBayAUtI+MBQgRY3lLoCt+eATxa6w8Q==" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['Form1']; if (!theForm) { theForm = document.Form1; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="/WebResource.axd?d=YcG_1mlPARhRW7O4sA9bWHA-qI2d_t_BO06OeFBhoaiREhheyXs3-1psdTUSDOHCoQeBPKlq2r8vu_cSQNfig-Is-AxTXJhRKwfH8V2oM9c1&t=638628512640000000" type="text/javascript"></script> <script src="/WebResource.axd?d=bIpPyEdzAMer_bwfyhWa6rFaO8WGfxnN2PvV0BTsVTDvSo40Rw6pGSZlPV1TZTu152c0lKoeiKGVeRIzWI8ylmApYjdRpTU999mo98-2hDs1&t=638628512640000000" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ function WebForm_OnSubmit() { if (typeof(ValidatorOnSubmit) == "function" && ValidatorOnSubmit() == false) return false; return true; } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="864D2D71" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAO8tONZ7TayD33kmU+szqoisK8Qcg6x7YEKBpnNUn26Cy8zACrOsmKsedR3ZCAsXqM/dy/xKCWXHGLwmCk3EueWC1wJCXuvUmCTQwrK8AlK4w==" /> </div> <header> <div style="background-color:#000;"> <div class="content-wrapper"> <div style="color:#fff;padding-bottom:22px;"> <span style="float:right;"> <ul class="lang"> <li style="font-size:12px;color:#ABA9A9;"> <a href="/"> TOP PAGE</a> </li> <li style="font-size:12px;color:#ABA9A9;"> </li> <li style="font-size:12px;color:#ABA9A9;background-color: #E55657; padding-top: 8px; padding-bottom: 4px; padding-left: 3px;"> <a href="/english/"> ENGLISH</a> </li> <li style="font-size:12px;color:#ABA9A9;"> </li> <li style="font-size:12px;color:#ABA9A9;"><a href="/japanese/"> JAPANESE</a></li> <li style="font-size:12px;color:#ABA9A9;"> | </li> <li style="font-size:12px;color:#fff;"> CONNECT WITH US:</li> <li class="nolink"> <a href="https://www.facebook.com/jcnnewswire" target="_blank" class="social"> <i class="fa fa-facebook-square"></i></a> </li> <li class="nolink"> <a href="https://twitter.com/JCNNewswire" target="_blank" class="social"><i class="fa fa-twitter-square"></i></a> </li> <li class="nolink"> <a href="/rssfeed/" class="social"><i class="fa fa-rss-square"></i></a> </li> </ul> </span> </div> </div> </div> <br /> <div class="content-wrapper"> <div class="feature-float-left"> <p class="site-title"><a href="../../../" id="A1"> <img src="/Images/JCN-Newswire.jpg" width="300px"/></a></p> </div> <div class="float-right"> <section id="login"> <ul> </ul> <ul class="the-icons"> </ul> </section> </div> <div class="row"> <div class="col-md-12 col-md-12-nav"> <nav class="topnav"> <ul class="nav nav-tabs"> <li role="presentation"><a href="../../../" id="A3">Home</a></li> <li role="presentation"><a href="../../../About/" id="A4">About</a></li> <li role="presentation"><a href="../../../services/" id="A13">Services</a></li> <li role="presentation"><a href="../../../Contact/" id="A5">Contact</a></li> <li role="presentation"><a href="http://client.japancorp.net" id="A6">Log in</a></li> <li style="padding-top:5px;"> <span id="RequiredFieldSearch" style="color:White;visibility:hidden;">*</span> <input name="ctl00$searchstring" type="text" id="searchstring" placeholder="Search for..." style="width:150px;height:30px;font-size:14px;" /><input type="submit" name="ctl00$SearchButton" value="Go!" onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$SearchButton", "", true, "", "", false, false))" id="SearchButton" class="btn btn-default" type="submit" style="height:30px;font-size: 13px;margin-left:2px;background-color:#f2f2f2;border-color:#ccc;" /> </li> </ul> </nav> </div> </div> </div> </header> <div id="body"> <section class="content-wrapper main-content clear-fix"> <!-- Go to www.addthis.com/dashboard to customize your tools --> <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-54f7fe387839d451" async="async"></script> <ol class="breadcrumb"> <li><a href="/english/">Home</a></li> <li class="active">Press release</li> </ol> <table> <!-- Body --> <tr valign="top"><td> <div class="col-lg-12 clearfix"> <table width="100%"> <tr> <td> <div id="MainContent_CompanyInfo"> <span id="MainContent_releaseDate" class="small">Nov 26, 2024 15:50 JST</span><br /> <span id="MainContent_companyLogo"><img src="http://www.jcnnewswire.com/image/company/eisai.240.jpg" class="companyLogo"></span><br /> <span id="MainContent_companySource" class="small">Source: <a href="http://www.eisai.com" target="_blank">Eisai</a></span> </div> </td> <td class="float-right"> <div class="addthis_sharing_toolbox"></div> </td> </tr> </table> </div> <p style="padding-bottom:100px;"></p> <div class="col-lg-9"> <table> <tr><td> <div align="justify" class="title"><span id="MainContent_HeadLine" class="header">Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan</span></div> <div align="justify"><strong></strong></div> <div align="justify"><span id="MainContent_Body" class="bodytext"><p><strong>TOKYO, Nov 26, 2024 - (JCN Newswire) - </strong>Eisai Co., Ltd. and Biogen Japan Ltd. announced today that Eisai has entered into a research collaboration agreement with the National Center of Neurology and Psychiatry to conduct apolipoprotein E (APOE) genetic testing in the dementia research and development program, “Development and Analysis of a National Clinical Registry of Disease-Modifying Therapies for Alzheimer’s Disease” (“AD-DMT Registry”). The research will be implemented by the Japan Agency forMedical Research and Development (AMED), with NCNP as the lead research institution.</p> <p>The APOE gene is known to be a risk factor for the onset of Alzheimer’s disease and is also associated with the frequency of amyloid-related imaging abnormalities (ARIA) in anti-amyloid β antibody treatments such as lecanemab (LEQEMBI®).(1)</p> <p>In Japan, at present, APOE genetic testing is not available for routine clinical practice under National Health Insurance. For thisreason, by using APOE genetic information collected in the AD-DMT Registry, Eisai and NCNP can further study the relationship between the APOE genotype and the safety and efficacy of treatment with lecanemab.</p> <p>Based on this research collaboration agreement with NCNP, Eisai will cover the cost of the APOE genetic testing conducted in the AD-DMT Registry. The findings, along with data collected from the lecanemab-specific post-marketing surveillance (all-casesurveillance), will be part of the reexamination of lecanemab’s application by the Japanese Pharmaceuticals and MedicalDevices Agency (PMDA) to ensure the label reflects the latest scientific understanding with the goal of improving patientoutcomes.</p> <p>Eisai and Biogen Japan will continue to contribute to the advancement of Alzheimer’s disease treatment through ongoing collaboration with academia.</p> <p>Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. (U.S.)co-commercializing and co-promoting the product and Eisai having final decision- making authority. In Japan, Eisai and Biogen Japan will co-promote lecanemab, with Eisai distributing the product as the Marketing Authorization Holder.</p> <p>(1) Foley KE and Wilcock DM (2024). Three major effects of APOEε4 on Aβ immunotherapy induced ARIA. Front. Aging Neurosci. 16:1412006. doi: 10.3389/fnagi.2024.1412006</p> <p><strong>About the “Development and Analysis of a National Clinical Registry of Disease-Modifying Therapies for Alzheimer’s Disease”</strong></p> <p>The National Center of Neurology and Psychiatry (NCNP) is the lead research institution for the dementia research and development program “Development and Analysis of a National Clinical Registry of Disease-Modifying Therapies for Alzheimer’s Disease” under the Japan Agency for Medical Research and Development (AMED). The research is being conducted with the aim of collecting clinical information and test data obtained from routine medical care using treatments including anti-amyloid β antibody drugs such as lecanemab, evaluate the efficacy and safety of these drugs, and perform blood sampling for APOE genotyping and measurement of other biomarkers in patients receiving the drugs. Some of theseresults will be reported to the participating patients, and the safety and efficacy of the drugs will be examined based on APOE genotype and other factors. Eisai plans to conduct large-scale and efficient research by sharing data of patients who have given their consent from the specific post-marketing surveillance.</p> <p>For more details on AMED's dementia research and development program, please visit the AMED <a href="https://www.amed.go.jp/en/program/list/14/05/012.html">website.</a></p> <p><strong>About Eisai</strong></p> <p>Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase thebenefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim toeffectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology, Oncology and Global Health.</p> <p>Theoria technologies Co., Ltd., a member of the Eisai Group, operates the dementia portal site "Theotol" (<a href="https://theotol.soudan-e65.com/">https://theotol.soudan-e65.com/</a>), which provides easy-to-understand contents and services for the general public aboutMCI and various types of dementia, their causes, treatments, as well as caregiving methods and personal experiences. (Japanese only)</p> <p><strong>About Biogen Japan</strong></p> <p>Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding ofhuman biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.</p> <p>We routinely post information on Biogen Japan that may be important to investors on our website at https://<a href="http://www.biogen.com/">www.biogen.com/</a> and social media <a href="https://www.facebook.com/BiogenJapan">Facebook,</a> <a href="https://twitter.com/BiogenJapan">Twitter,</a> <a href="https://www.instagram.com/biogenjapan">Instagram,</a> <a href="https://www.youtube.com/BiogenJapan">YouTube,</a> <a href="https://www.linkedin.com/company/biogen-">LinkedIn,</a> <a href="https://page.line.me/biogen">LINE.</a><br><br></p> <p><strong>Media Contacts:</strong></p> <p>Eisai Co., Ltd.<br>Public Relations Department <br>TEL: +81 (0)3-3817-5120</p> <p>Biogen Japan, Ltd.<br>Corporate Affairs<br>TEL: ＋81-70-1501-4315<br>E-mail: <a href="mailto:Japan-PA@biogen.com">Japan-PA@biogen.com</a></p></span></div> <div align="justify"><span id="MainContent_CompanyName" class="bodytext"></span></div> <div align="justify"><span id="MainContent_CompanyBoiler" class="bodytext"></span></div> <div align="justify"><span id="MainContent_Contact" class="bodytext"></span></div> <div align="justify"><span id="MainContent_Source" class="note">Source: Eisai<BR />Sectors: BioTech <BR /><BR /></span></div> <div align="justify"><span id="MainContent_Copyright" class="bodytext"><p>Copyright 漏2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.<p></span></div> </td></tr> </table> </div> <div class="col-lg-3"> <span id="MainContent_RelatedNews_RelatedNews"><div><h4>Related Press Release</h4><hr /><table width="100%" cellpadding=0 cellspacing=0><tr><td><a href="/english/pressrelease/96235/3/Eisai-Selected-for-"Human-Capital-Leaders-2024"-and-"Human-Capital-Management-Gold-Quali">Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives</a></td></tr><tr><td class="note">February 20 2025 12:29 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/96056/3/Development-of-Prediction-Model-for-Brain-Amyloid-Beta-Accumulation-for-Early-Screening-of-Alzheimer">Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease</a></td></tr><tr><td class="note">February 14 2025 11:09 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/95722/3/Eisai-to-Provide-Guidance-on-Reducing-the-Risk-of-Cognitive-Decline-and-Nutrition,-and-Development-G">Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies</a></td></tr><tr><td class="note">February 03 2025 16:23 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/95573/3/FDA-Approves-LEQEMBI-(lecanemab-irmb)-IV-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer&apo">FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease</a></td></tr><tr><td class="note">January 28 2025 08:46 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/95425/3/Eisai-Listed-as-a-Global-100-Most-Sustainable-Corporation-for-The-Ninth-Time-Highest-Ranked-Global-P">Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company</a></td></tr><tr><td class="note">January 22 2025 16:18 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/95256/3/FDA-Accepts-LEQEMBI-(lecanemab-irmb)-Biologics-License-Application-for-Subcutaneous-Maintenance-Dosi">FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease</a></td></tr><tr><td class="note">January 15 2025 09:03 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/95040/3/Elucidation-of-part-of-the-Mechanism-by-which-Lecanemab-Slows-the-Progression-of-Alzheimer&aposs-Dis">Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease</a></td></tr><tr><td class="note">January 07 2025 08:14 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/94804/3/Fujirebio-and-Eisai-Enter-into-Memorandum-of-Understanding-for-Joint-Research-and-Social-Implementat">Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases</a></td></tr><tr><td class="note">December 23 2024 16:22 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/94481/3/Eisai&aposs-"URECE(R)"-(Dotinurad)-Approved-in-China-for-Gout-Patients-with-Hyperuricemia">Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia</a></td></tr><tr><td class="note">December 11 2024 13:45 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/94344/3/"LEQEMBI"-(Lecanemab)-Approved-for-the-Treatment-of-Early-Alzheimer&aposs-Disease-in-Mexico">"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico</a></td></tr><tr><td class="note">December 05 2024 10:22 JST</td></tr><tr><td> </td></tr><tr><td align="center"><a href="/english/CompanyNews/94087/3">More Press release >></a></td></tr></table></dl></div></span> <br /> <h4><span id="MainContent_Label1">Latest Press Release</span></h4> <hr /> <span id="MainContent_LatestRelease_LatestPressRelease"><table width="100%" cellpadding=0 cellspacing=0><tr><td class="articleDate"><img title="Fujitsu Ltd" src="http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg"><br /><a href="/english/pressrelease/96372/3/Fujitsu,-ANA-X,-Toshiba-Data,-and-Kawasaki-City-launch-Japans-first-pilot-program-to-quantify-citize" class="newslink">Fujitsu, ANA X, Toshiba Data, and Kawasaki City launch Japan's first pilot program to quantify citizen CO2 reduction</a><br /><span class="note"> Feb 25, 2025 11:24 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Corporation" src="http://www.jcnnewswire.com/image/toppage/MC.68.jpg"><br /><a href="/english/pressrelease/96336/3/Mitsubishi-and-ENEOS-to-conduct-Front-End-Engineering-Design-for-Sustainable-Aviation-Fuel-(SAF)-Pro" class="newslink">Mitsubishi and ENEOS to conduct Front End Engineering Design for Sustainable Aviation Fuel (SAF) Production at the Wakayama Refinery</a><br /><span class="note"> Feb 24, 2025 12:30 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Soligenix, Inc" src="http://www.jcnnewswire.com/image/toppage/Soligenix.68.jpg"><br /><a href="/english/pressrelease/96307/3/Soligenixs-Leadership-Aims-to-Drive-Growth-in-Rare-Disease-Markets-in-2025-and-2026" class="newslink">Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026</a><br /><span class="note"> Feb 22, 2025 04:50 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Honda Motor Co, Ltd" src="http://www.jcnnewswire.com/image/toppage/honda.gif"><br /><a href="/english/pressrelease/96289/3/Honda-Receives-Highest-Ranking-of-3-Stars-as-Part-of-FIA-Road-Safety-Index,-Tool-for-Organizations-a" class="newslink">Honda Receives Highest Ranking of 3 Stars as Part of FIA Road Safety Index, Tool for Organizations and Companies to Measure Their Road Safety Footprint</a><br /><span class="note"> Feb 21, 2025 19:40 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Honda Motor Co, Ltd" src="http://www.jcnnewswire.com/image/toppage/honda.gif"><br /><a href="/english/pressrelease/96288/3/Honda-Partners-with-United-Nations-Road-Safety-Fund-(UNRSF)-to-Work-Toward-Reduction-of-Fatalities-f" class="newslink">Honda Partners with United Nations Road Safety Fund (UNRSF) to Work Toward Reduction of Fatalities from Traffic Collisions</a><br /><span class="note"> Feb 21, 2025 19:11 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Corporation" src="http://www.jcnnewswire.com/image/toppage/MC.68.jpg"><br /><a href="/english/pressrelease/96271/3/Mitsubishi-Logistics-Corporation,-Mitsubishi-Corporation,-and-Yourstand-Inc-Advancing-Completely-CO2" class="newslink">Mitsubishi Logistics Corporation, Mitsubishi Corporation, and Yourstand Inc. Advancing Completely CO2-Free Electrification of Pharmaceutical Transportation</a><br /><span class="note"> Feb 21, 2025 15:01 JST</span><br /></td></tr><tr><td class="articleDate"><img title="NEC Corporation" src="http://www.jcnnewswire.com/image/toppage/NEC.62.jpg"><br /><a href="/english/pressrelease/96270/3/NEC-Innovation-Challenge-awards-Canadas-Prevu3D-Inc-with-the-NEC-Award-and-NOFF-Award" class="newslink">NEC Innovation Challenge awards Canada's Prevu3D Inc. with the NEC Award and NOFF Award</a><br /><span class="note"> Feb 21, 2025 14:39 JST</span><br /></td></tr><tr><td class="articleDate"><img title="NEC Corporation" src="http://www.jcnnewswire.com/image/toppage/NEC.62.jpg"><br /><a href="/english/pressrelease/96263/3/NEC-Develops-Near-Real-time-RIC-for-High-Performance-5G-vRAN" class="newslink">NEC Develops Near Real-time RIC for High Performance 5G vRAN</a><br /><span class="note"> Feb 21, 2025 12:00 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /><a href="/english/pressrelease/96235/3/Eisai-Selected-for-Human-Capital-Leaders-2024-and-Human-Capital-Management-Gold-Quality-for-Second-C" class="newslink">Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives</a><br /><span class="note"> Feb 20, 2025 13:29 JST</span><br /></td></tr><tr><td class="articleDate"><img title="NEC Corporation" src="http://www.jcnnewswire.com/image/toppage/NEC.62.jpg"><br /><a href="/english/pressrelease/96234/3/NEC-X-&-Carbide-Ventures-Partner-To-Rapidly-Accelerate-Early-Stage-Startups" class="newslink">NEC X & Carbide Ventures Partner To Rapidly Accelerate Early-Stage Startups</a><br /><span class="note"> Feb 19, 2025 20:16 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Power" src="http://www.jcnnewswire.com/image/toppage/mitsubishipower.68.jpg"><br /><a href="/english/pressrelease/96213/3/Mitsubishi-Power-Advances-Bahrains-Industrial-Growth-with-Completion-of-Albas-Power-Station-5-Block-" class="newslink">Mitsubishi Power Advances Bahrain's Industrial Growth with Completion of Alba's Power Station 5 Block 4 Combined Cycle Power Plant Project</a><br /><span class="note"> Feb 19, 2025 16:54 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Honda Motor Co, Ltd" src="http://www.jcnnewswire.com/image/toppage/honda.gif"><br /><a href="/english/pressrelease/96195/3/Honda-Reveals-Specification-for-its-Next-generation-Fuel-Cell-Module" class="newslink">Honda Reveals Specification for its Next-generation Fuel Cell Module</a><br /><span class="note"> Feb 19, 2025 11:07 JST</span><br /></td></tr><tr><td class="articleDate"><img title="NEC Corporation" src="http://www.jcnnewswire.com/image/toppage/NEC.62.jpg"><br /><a href="/english/pressrelease/96193/3/NEC-Orchestrating-Future-Fund-invests-in-Aetion,-a-US-based-provider-of-healthcare-analytics-platfor" class="newslink">NEC Orchestrating Future Fund invests in Aetion, a U.S.-based provider of healthcare analytics platforms</a><br /><span class="note"> Feb 19, 2025 09:08 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Heavy Industries, Ltd." src="http://www.jcnnewswire.com/image/toppage/MHI_newT.jpg"><br /><a href="/english/pressrelease/96172/3/Osaka-Gas-and-MHI-Launch-CO2NNEX-Digital-Platform-for-Management-and-Transfer-of-Clean-Gas-Certifica" class="newslink">Osaka Gas and MHI Launch CO2NNEX Digital Platform for Management and Transfer of Clean Gas Certificates for e-Methane, for Use during Expo 2025</a><br /><span class="note"> Feb 18, 2025 13:18 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Toyota Motor Corporation" src="http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg"><br /><a href="/english/pressrelease/96133/3/TOYOTA-GAZOO-Racing-starts-WEC-season-with-Qatar-challenge" class="newslink">TOYOTA GAZOO Racing starts WEC season with Qatar challenge</a><br /><span class="note"> Feb 17, 2025 18:45 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Honda Motor Co, Ltd" src="http://www.jcnnewswire.com/image/toppage/honda.gif"><br /><a href="/english/pressrelease/96131/3/FLAT-OUT-IN-TOKYO-Red-Bull-Showrun-x-Powered-by-Honda-April-2-(Wed)" class="newslink">FLAT OUT IN TOKYO "Red Bull Showrun x Powered by Honda" April 2 (Wed)</a><br /><span class="note"> Feb 17, 2025 16:21 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Toyota Motor Corporation" src="http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg"><br /><a href="/english/pressrelease/96129/3/Thrilling-TOYOTA-GAZOO-Racing-one-two-on-Swedish-snow" class="newslink">Thrilling TOYOTA GAZOO Racing one-two on Swedish snow</a><br /><span class="note"> Feb 17, 2025 14:23 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Corporation" src="http://www.jcnnewswire.com/image/toppage/MC.68.jpg"><br /><a href="/english/pressrelease/96127/3/Launch-of-Joint-Demonstration-Experiment-of-Remote-Provision-of-GPU-Computing-Power" class="newslink">Launch of Joint Demonstration Experiment of Remote Provision of GPU Computing Power</a><br /><span class="note"> Feb 17, 2025 14:10 JST</span><br /></td></tr><tr><td class="articleDate"><img title="mazda" src="http://www.jcnnewswire.com/image/toppage/MazdaLogo.48.jpg"><br /><a href="/english/pressrelease/96066/3/Mazda-to-Strengthen-Production-and-Sales-Systems-in-Thailand" class="newslink">Mazda to Strengthen Production and Sales Systems in Thailand</a><br /><span class="note"> Feb 14, 2025 17:04 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Toyota Motor Corporation" src="http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg"><br /><a href="/english/pressrelease/96060/3/Toyota-Develops-New-Fuel-Cell-System" class="newslink">Toyota Develops New Fuel Cell System</a><br /><span class="note"> Feb 14, 2025 15:27 JST</span><br /></td></tr></table></span> <a id="MainContent_LatestRelease_MoreRelease" href="/english/MoreNews/3/">More Latest Release >></a> </div> </td></tr> </table> <script type="text/javascript"> $(document).ready(function () { $("#single_1").fancybox({ helpers: { title: { type: 'float' } } }); }); </script> </section> </div> <footer> <div class="content-wrapper"> <div align="center"> Copyright © 2025 - JCN Newswire <div class="botton-nav"> <ul> <li><a href="../../../../" id="A7">Home</a></li> <li><a href="../../../about/" id="A8">About</a></li> <li><a href="../../../contact/" id="A9">Contact</a></li> <li><a href="../../../../rssfeed/" id="A10">RSS</a></li> <li><a href="../../../Cookies/">Cookies Policy</a></li> <li><a href="../../../Disclaimer/">Disclaimer</a></li> <li><a href="../../../Privacy/">Privacy Policy</a></li> <li><a href="../../../Terms/">Terms of Use</a></li> <li> - </li> <li> Connect with us:</li> <li class="nolink"> <a href="https://www.facebook.com/jcnnewswire" target="_blank" class="social"> <i class="fa fa-facebook-square"></i></a> </li> <li class="nolink"> <a href="https://twitter.com/JCNNewswire" target="_blank" class="social"><i class="fa fa-twitter-square"></i></a> </li> <li class="nolink"> <a href="/rssfeed/" class="social"><i class="fa fa-rss-square"></i></a> </li> </ul> </div> </div> </div> </footer> <script type="text/javascript"> //<![CDATA[ var Page_Validators = new Array(document.getElementById("RequiredFieldSearch")); //]]> </script> <script type="text/javascript"> //<![CDATA[ var RequiredFieldSearch = document.all ? document.all["RequiredFieldSearch"] : document.getElementById("RequiredFieldSearch"); RequiredFieldSearch.controltovalidate = "searchstring"; RequiredFieldSearch.errormessage = "*"; RequiredFieldSearch.evaluationfunction = "RequiredFieldValidatorEvaluateIsValid"; RequiredFieldSearch.initialvalue = ""; //]]> </script> <script type="text/javascript"> //<![CDATA[ var Page_ValidationActive = false; if (typeof(ValidatorOnLoad) == "function") { ValidatorOnLoad(); } function ValidatorOnSubmit() { if (Page_ValidationActive) { return ValidatorCommonOnSubmit(); } else { return true; } } //]]> </script> </form> <script> (function (i, s, o, g, r, a, m) i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () (i[r].q = i[r].q || []).push(arguments) }, i[r].l = 1 * new Date(); a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g; m.parentNode.insertBefore(a, m) })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga'); ga('create', 'UA-61831624-1', 'auto'); ga('send', 'pageview'); </script> </body> </html>